{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:37:59Z","timestamp":1782398279653,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rare diseases affect &gt;\u2009400 million people globally with a disproportionate burden falling on children, resulting in high morbidity and mortality rates. Affected individuals in some under-resourced countries have limited access to expert care or treatments; moreover, they suffer long diagnostic journeys during which debilitating and life-threatening complications occur. Lysosomal storage disorders (LSD) are prototype rare diseases due, in the main, to inherited deficiencies of lysosomal enzymes\/transporters that affect up to 1 in 5000 newborns. Recognizing the need to provide treatment access to people with LSDs everywhere, a collaborative partnership was pioneered and set up 30\u00a0years ago. Partnering with local authorities, non-government organizations across six continents, local as well as international experts, a robust, sustainable Humanitarian Program emerged that now represents the most enduring charitable access program for LSD treatment. Here we present the history, process, lasting beneficial effect of the program to develop healthcare systems and infrastructures, and the lessons learned from addressing major unmet needs for LSDs.\n<\/jats:p>","DOI":"10.1186\/s13023-022-02192-1","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:02:24Z","timestamp":1649030544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Transformative effect of a Humanitarian Program for individuals affected by rare diseases: building support systems and creating local expertise"],"prefix":"10.1186","volume":"17","author":[{"given":"I. C.","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"El-Beshlawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tylki-Szyma\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-L.","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Collin-Histed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Schoneveld","family":"van der Linde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. C.","family":"D\u0169ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3447-6421","authenticated-orcid":false,"given":"Pramod K.","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"key":"2192_CR1","unstructured":"Global Genes. https:\/\/globalgenes.org\/."},{"key":"2192_CR2","unstructured":"Global Rare Disease Commission Report. https:\/\/www.globalrarediseasecommission.com\/Report\/."},{"issue":"1","key":"2192_CR3","first-page":"87","volume":"26","author":"S Bruni","year":"2007","unstructured":"Bruni S, Loschi L, Incerti C, Gabrielli O, Coppa GV. Update on treatment of lysosomal storage diseases. Acta Myol. 2007;26(1):87\u201392.","journal-title":"Acta Myol"},{"issue":"24","key":"2192_CR4","doi-asserted-by":"publisher","first-page":"476","DOI":"10.21037\/atm.2018.11.39","volume":"6","author":"A Sun","year":"2018","unstructured":"Sun A. Lysosomal storage disease overview. Ann Transl Med. 2018;6(24):476.","journal-title":"Ann Transl Med"},{"issue":"2","key":"2192_CR5","doi-asserted-by":"publisher","first-page":"e12836","DOI":"10.15252\/emmm.202012836","volume":"13","author":"G Parenti","year":"2021","unstructured":"Parenti G, Medina DL, Ballabio A. The rapidly evolving view of lysosomal storage diseases. EMBO Mol Med. 2021;13(2):e12836.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"2192_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13023-020-01645-9","volume":"16","author":"A Mehta","year":"2021","unstructured":"Mehta A, Ramaswami U, Muenzer J, Giugliani R, Ullrich K, Collin-Histed T, et al. A charitable access program for patients with lysosomal storage disorders in underserved communities worldwide. Orphanet J Rare Dis. 2021;16(1):8.","journal-title":"Orphanet J Rare Dis"},{"key":"2192_CR7","unstructured":"Sanofi Genzyme. Sanofi Genzyme Humanitarian Programs. https:\/\/www.sanofigenzyme.com\/en\/responsibility\/humanitarian-programs."},{"key":"2192_CR8","unstructured":"Bartlett CA, McLean AN. Genzyme's Gaucher Initiative: global risk and responsibility. Harvard Business School Case 1048 ed."},{"issue":"2","key":"2192_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/trstmh\/trab015","volume":"115","author":"DH Molyneux","year":"2021","unstructured":"Molyneux DH, Asamoa-Bah A, Fenwick A, Savioli L, Hotez P. The history of the neglected tropical disease movement. Trans R Soc Trop Med Hyg. 2021;115(2):169\u201375.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2192_CR10","first-page":"81","volume":"6","author":"PB Deegan","year":"2012","unstructured":"Deegan PB, Cox TM. Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des Dev Ther. 2012;6:81\u2013106.","journal-title":"Drug Des Dev Ther"},{"key":"2192_CR11","unstructured":"Sanofi Genzyme. Addressing the needs of rare disease patients around the world 2019. https:\/\/www.sanofi.com\/-\/media\/Project\/One-Sanofi-Web\/Websites\/Global\/Sanofi-COM\/Home\/common\/docs\/our-responsibility\/documents-center\/factsheets-2020\/addressing-the-needs-of-rare-disease-patients.pdf?la=en."},{"issue":"1","key":"2192_CR12","doi-asserted-by":"publisher","first-page":"I29","DOI":"10.1186\/1755-8166-7-S1-I29","volume":"7","author":"M Muranjan","year":"2014","unstructured":"Muranjan M. Enzyme replacement therapy for lysosomal storage disorders in India. Mol Cytogenet. 2014;7(1):I29.","journal-title":"Mol Cytogenet"},{"issue":"4","key":"2192_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4103\/jpgm.JPGM_41_18","volume":"64","author":"M Muranjan","year":"2018","unstructured":"Muranjan M, Karande S. Enzyme replacement therapy in India: lessons and insights. J Postgrad Med. 2018;64(4):195\u20139.","journal-title":"J Postgrad Med"},{"issue":"1","key":"2192_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/jmd2.12156","volume":"56","author":"S Nampoothiri","year":"2020","unstructured":"Nampoothiri S, Yesodharan D, Bhattacherjee A, Ahamed H, Puri RD, Gupta N, et al. Fabry disease in India: a multicenter study of the clinical and mutation spectrum in 54 patients. JIMD Rep. 2020;56(1):82\u201394.","journal-title":"JIMD Rep"},{"key":"2192_CR15","doi-asserted-by":"crossref","unstructured":"Puri RD, Setia N, Narayan V, Jagadeesh S, Nampoothiri S, Gupta N, et al. Late onset Pompe disease in India\u2014beyond the Caucasian phenotype. Neuromuscul Disord NMD. 2021;31(5):431\u201341.","DOI":"10.1016\/j.nmd.2021.02.013"},{"issue":"1","key":"2192_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bcmd.2009.09.006","volume":"44","author":"CE Hollak","year":"2010","unstructured":"Hollak CE, vom Dahl S, Aerts JM, Belmatoug N, Bembi B, Cohen Y, et al. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis. 2010;44(1):41\u20137.","journal-title":"Blood Cells Mol Dis"},{"key":"2192_CR17","volume-title":"Conscience and courage: how visionary CEO Henri Termeer built a biotech giant and pioneered the rare disease industry","author":"J Hawkins","year":"2019","unstructured":"Hawkins J. Conscience and courage: how visionary CEO Henri Termeer built a biotech giant and pioneered the rare disease industry. New York: Cold Spring Harbor Laboratory Press; 2019."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02192-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02192-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02192-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:03:57Z","timestamp":1649030637000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02192-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2192"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02192-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,4]]},"assertion":[{"value":"8 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided informed consent to participate in the program.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent was obtained to publish images of individuals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AM has received consulting fees from Alexion, BioMarin, Chiesi, Sanofi Genzyme, Takeda, and Ultragenix; travel and congress sponsorship and fees for lectures from Alexion, Biomarin, Sanofi Genzyme, Takeda, and Ultragenix; and research grants from Alexion, BioMarin, Sanofi Genzyme, and Takeda. TCH has received research grants from Sanofi Genzyme and served on advisory boards for Sanofi Genzyme. MSvdL has received consulting fees from Amicus Therapeutics, Gilead Sciences, International Pompe Association, and Sanofi Genzyme. Her work in the Humanitarian Program never has been paid and was done on a voluntary basis. PKM has received research grant and travel support from Sanofi Genzyme. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}